Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-10T08:05:20.928Z Has data issue: false hasContentIssue false
  • English
  • Français

Canadian Headache Society Guideline for Migraine Prophylaxis: Supplement 2

Published online by Cambridge University Press:  02 December 2014

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 39 , Issue S2 , March 2012 , pp. i - 63
Copyright
Copyright © The Canadian Journal of Neurological 2012

References

1Pryse-Phillips, W, Findlay, H, Tugwell, P, Edmeads, J, Murray, TJ, Nelson, RF.A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache. Can J Neurol Sci. 1992 Aug;19(3):333–9.Google Scholar
2O’Brien, B, Goeree, R, Streiner, D.Prevalence of migraine headache in Canada: a population-based survey. Int J Epidemiol. 1994 Oct; 23(5):1020–6.Google Scholar
3Cooke, LJ, Becker, WJ.Migraine prevalence, treatment and impact: the Canadian women and migraine study. Can J Neurol Sci. 2010; 37:580–7.Google Scholar
4Leonardi, M, Steiner, T, Scher, A, Lipton, RB.The global burden of migraine: measuring disability in headache disorders with WHO’s classification of functioning, disability and health (ICF). J Headache Pain. 2005;6:429–40.CrossRefGoogle ScholarPubMed
5Zeeberg, P, Olesen, J, Jensen, R.Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology. 2006;66:1894–8.CrossRefGoogle ScholarPubMed
6Headache Classification Subcommittee of the International Headache Society The International Classification of headache disorders. Cephalalgia. 2004;24(Suppl 1):9–160.Google Scholar
7Jelinski, SE, Becker, WJ, Christie, SN, et al.Clinical features and pharmacological treatment of migraine patients referred to headache specialists in Canada. Cephalalgia. 2006;26:578–88.Google Scholar
8Silberstein SD and the US Headache Consortium. Pracitce Parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Neurology. 2000;55:754–62.Google Scholar
9Pryse-Phillips, WEM, Dodick, DW, Edmeads, JG, et al.Guidelines for the diagnosis and management of migraine in clinical practice. CMAJ. 1997;156: 1273–87.Google Scholar
10Lipton, RB, Bigal, ME, Diamond, M, Freitag, F, Reed, ML, Stewart, WF and the AMPP Advisory Group. Migraine Prevalence, disease burden, and the need for preventative therapy. Neurology. 2007; 68:343–9.Google Scholar
11Mathew, N, Saper, J, Silberstein, S, Rankin, L, Markley, H.Migraine prophylaxis with divalproex. Arch Neurol. 1995;52(3):281–6.CrossRefGoogle ScholarPubMed
12Klapper, J.Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17:103–8.CrossRefGoogle ScholarPubMed
13Brandes, JL, Saper, JR, Diamond, M, et al.Topiramate for Migraine Prevention. JAMA. 2004;291:965–73.CrossRefGoogle ScholarPubMed
14Jensen, R, Brinck, T, Olesen, J.Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994;44:647–51.Google Scholar
15Diener, HC, Agosti, R, Allais, G, Bergmans, P, bussoni, G, Davies, B, Ertas, M, for the TOPMAT- MIG 303 Investigator Group. Cessation versus continuation of 6-month migraine preventative therapy with topiramate (PROMPT): a randomised, double-blind placebo-controlled trial. Lancet Neurol. 2007;6:1054–62.Google Scholar
16Becker, WJ, Christie, SN, Ledoux, S, Binder, C.Topiramate prophylaxis and response to triptan treatment for acute migraine. Headache. 2006;46:1424–30.CrossRefGoogle ScholarPubMed
17Ziegler, DK, Hurwitz, A, Preskorn, S, Hassanein, R, Seim, J.Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. Arch Neurol. 1993;50: 825–30.Google Scholar
18Woeber, C, Woeber-Bingol, C, Koch, G, Wessely, P.Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia. 1991;11:251–6.Google Scholar
19Sorensen, PS, Hansen, K, Olesen, J.A placebo-contolled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia. 1986;6:7–14.Google Scholar
20Members of the Task Force: Evers, S, Afra, J, Frese, A, Goadsby, PJ, Linde, M, May, A, Sandor, PS.EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol. 2009;16:968–81.CrossRefGoogle ScholarPubMed
21Diener, H-C, Bussone, G, Van Oene, JC, Lahaye, M, Schwalen, S, Goadsby, PJ, TOPMAT - MIG 201 (TOP- Chrome) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–2.Google Scholar
22Mei, D, Ferraro, D, Zelano, G, et al.Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol. 2006;29:269–75.Google Scholar
23Aurora, SK, Dodick, DW, Turkel, CC, DeGryse, RE, Silberstein, SD, Lipton, RB, Diener, HC, Brin, MF; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30: 793–803.Google Scholar
24Diener, HC, Dodick, DW, Aurora, SK, Turkel, CC, DeGryse, RE, Lipton, RB, et al; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–14.Google Scholar
25Hagen, K, Albretsen, C, Vilming, ST, et al.Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia. 2009;29:221–32.Google Scholar
26Katsarava, Z, Schneeweiss, S, Kurth, Tet al.Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004;62:788–90.Google Scholar
27Limmroth, V, Biondi, D, Pfeil, J, Schwalen, S.Topiramate in patients with episodic migraine: Reducing the risk for chronic forms of headache. Headache. 2007;47:13–21.Google Scholar
28Lipton, RB, Silberstein, S, Dodick, D, et al.Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 2011;31:18–30.CrossRefGoogle ScholarPubMed
29Headache Classification Subcommittee of the International Headache Society. The International Classification of headache disorders. Cephalalgia. 2004;24 Suppl 1:9–160.Google Scholar
30Ad Hoc Committee on Classification of Headache. JAMA. 1962;179:717–18.Google Scholar
31Pringsheim, T, Davenport, WJ, Becker, WJ.Prophylaxis of migraine headache. CMAJ. 2010;182:679–85.CrossRefGoogle ScholarPubMed
32Harris, RD, Helfand, M, Woolf, SH, et al.Current methods of the US preventive services task force. Areview of the process. Am J Prev Med. 2001;20(3S):21–35.CrossRefGoogle Scholar
33Guyatt, GH, Oxman, AD, Vist, GE, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336;924–6.Google Scholar
34Guyatt, GH, Oxman, AD, Kunz, R, et al.What is “quality of evidence” and why is it important to clinicians? BMJ. 2008 May 3;336(7651):995–8.CrossRefGoogle Scholar
35Balshem, H, Helfand, M, Schuenemann, HJ, et al.GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–6.Google Scholar
36Cuello García, CA, Pacheco Alvarado, KP, Pérez Gaxiola, G. Grading recommendations in clinical practice guidelines: randomised experimental evaluation of four different systems. Arch Dis Child. 2011 May 19.Google Scholar
37Brożek, JL, Akl, EA, Compalati, E, et al.Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy. 2011 May;66(5):588–95.Google Scholar
38Mathew, N, Saper, J, Silberstein, S, Rankin, L, Markley, H.Migraine prophylaxis with divalproex. Arch Neurol. 1995;52(3):281–6.Google Scholar
39Klapper, J.Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17:103–8.CrossRefGoogle ScholarPubMed
40Freitag, FG, Collins, SD, Carlson, HA, et al.A randomized trial of divalproex sodium extended release tablets in migraine prophylaxis. Neurology. 2002;58:1652–9.Google Scholar
41Hering, R, Kuritzky, A.Sodium valproate in the prophylactic treatment of migraine: a double blind study versus placebo. Cephalalgia. 1992;12:81–4.Google Scholar
42Jensen, R, Brinck, T, Olesen, J.Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994;44:647–51.Google Scholar
43DiTrapani, B, Mei, D, Marra, C, Capuano, A.Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo controlled study. Clin Ter. 2000;151:145–8.Google Scholar
44Mathew, N, Rapoport, A, Saper, J, et al.Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41:119–28.Google Scholar
45Brandes, JL, Saper, JR, Diamond, M, et al.Topiramate for Migraine Prevention. JAMA. 2004;291:965–73.Google Scholar
46Silberstein, S, Neto, W, Schmitt, J, Jacobs, D.Topiramate in migraine prevention. Arch Neurol. 2004;61:490–5.Google Scholar
47Diener, H, Tfelt-Hansen, P, Dahlof, C, et al.Topiramate in migraine prophylaxis. J Neurol. 2004;251:943–50.Google Scholar
48Mei, D, Capuano, A, Vollono, C, et al.Topiramate in migraine prophylaxis: a randomized double blind versus placebo study. Neurol Sci. 2004;25:245–50.Google ScholarPubMed
49Silberstein, S, Hulihan, J, Karim, R, et al.Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo controlled, double blind, 12-week pilot study. Clin Ther. 2006;28(7):1002–11.Google Scholar
50Storey, JR, Calder, CS, Hart, DE, Potter, DL.Topiramate in Migraine Prevention: A double blind, placebo-controlled study. Headache. 2001;41:968–75.Google Scholar
51Shaygannejad, V, Janghorbani, M, Ghorbani, A, Ashtari, F, Zakizade, N, Nasr, V.Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache. 2006;46:642–8.CrossRefGoogle ScholarPubMed
52Gupta, P, Singh, S, Goyal, V, Shukla, B, Behari, M.Low dose topiramate versus lamotrigine in migraine prophylaxis (the lotolamp study). Headache. 2007;47:402–12.Google Scholar
53Dodick, DW, Freitag, F, Banks, J, et al.Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009 Mar;31(3):542–59.Google Scholar
54Keskinbora, K, Aydinli, I.A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg. 2008 Dec;110 (10):979–84.Google Scholar
55Ashtari, F, Shaygannejad, V, Akbari, M.A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand. 2008 Nov;118(5):301–5.Google Scholar
56Lipton, RB, Silberstein, S, Dodick, D, et al.Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 2011 Jan;31(1):18–30.Google Scholar
57Lo, YL, Lum, SY, Fook-Chong, S, et al.A pilot study of topiramate dosages for migraine prophylaxis in an Asian population. J Headache Pain. 2010 Apr;11(2):175–8.Google Scholar
58Millán-Guerrero, RO, Isais-Millán, R, Barreto-Vizcaíno, S, et al.Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study. Eur Neurol. 2008;59(5):237–42.CrossRefGoogle ScholarPubMed
59Gomersall, JD, Stuart, A.Amitriptyline in migraine prophylaxis. J Neurol Neurosurg Psychiatry. 1973;36:684–90.Google Scholar
60Ziegler, DK, Hurwitz, A, Hassanein, RS.Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol. 1987;44:486–9.Google Scholar
61Bank, J.A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache. 1994;34:476–8.Google Scholar
62Couch, JR, Hassanein, RS.Amitriptyline in migraine prophylaxis. Arch Neurol. 1979;36:695–9.Google Scholar
63Jackson, JL, Shimeall, W, Sessums, L, et al.Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010;341:c5222 doi:10.1136/bmj.c5222.Google Scholar
64Ozyalcin, S, Talu, GK, Kiziltan, E, Yucel, B, Ertas, M, Disci, R.The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005;45:144–52.Google Scholar
65Bulut, S, Berilgen, MS, Baran, A, Tekatas, A, Atmaca, M, Mungen, B.Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg. 2004;107:44–8.Google Scholar
66Linde, K, Rossnagel, K.Propranolol for migraine prophylaxis. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.:CD003225.DOI:10.1002/14651858.CD003225.pub2.Google Scholar
67Freitag, FG, Diamond, S.Nadolol and placebo comparison study in the prophylactic treatment of migraine. J Am Osteopath Assoc. 1984;84(4):343–7.CrossRefGoogle ScholarPubMed
68Ryan, RE, Ryan, RE, Sudilovsky, A.Nadolol and placebo comparison study in the prophylactic treatment of migraine. Panminerva Med. 1982;24(2):89–94.Google Scholar
69Sorensen, PS, Hansen, K, Olesen, J.A placebo-contolled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia. 1986;6:7–14.Google Scholar
70Frenken, CW, Nuijten, ST.Flunarizine, a new preventive approach to migraine. Clin Neurol Neurosurg. 1984:86(1):17–20.Google Scholar
71Mendenopoulos, G, Manafi, TH, Logothetis, I, Bostantjopoulos, S.Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia. 1985;5:31–7.Google Scholar
72Louis, P.A double blind placebo-controlled prophylactic study of flunarizine in migraine. Headache. 1981;21:235–9.Google Scholar
73Al Deeb, SM, Biary, N, Bahou, Y, Al Jaberi, M, Khoja, W.Flunarizine in migraine: a double blind placebo-controlled study (in a Saudi population). Headache. 1992;32:461–2.Google Scholar
74Thomas, M, Behari, M, Ahuja, GK.Flunarizine in migraine prophylaxis: an Indian trial. Headache. 1991;31:613–15.Google Scholar
75Cerbo, R, Casacchia, M, Formisano, R, et al.Flunarizine-pizotifen single dose double blind crossover trial in migraine prophylaxis. Cephalalgia. 1986;6:15–18.Google Scholar
76Rascol, A, Montastruc, JL, Rascol, O.Flunarizine versus pizotifen: a double blind study in the prophylaxis of migraine. Headache. 1986;26:83–5.CrossRefGoogle ScholarPubMed
77Louis, P, Spierlings, EL.Comparison of flunarizine and pizotifen in migraine treatment: a double blind study. Cephalalgia. 1982;2:197–203.Google Scholar
78Markley, HG, Cheronis, J, Piepho, RW.Verapamil in prophylactic therapy of migraine. Neurology. 1984;34:973–6.Google Scholar
79Soloman, GD, Steel, JG, Spaccavento, LJ.Verapamil prophylaxis of migraine. JAMA. 1983;250:2500–2.Google Scholar
80Schrader, H, Stovner, LJ, Helde, G, Sand, T, Bovim, G.Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomized, placebo-controlled, crossover study. BMJ. 2001;322:1–5.Google Scholar
81Tronvik, E, Stovner, LJ, Helde, G, Sand, T, Bovin, G.Prophylactic treatment of migraine with an angiotensin II receptor blocker. JAMA. 2003;289:65–9.Google Scholar
82Diener, HC, Gendolla, A, Feuersenger, A, et al.Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia. 2009 Sep;29(9):921–7.Google Scholar
83Schoenen, J, Jacquy, J, Lenaerts, M.Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial. Neurology. 1998;50(2):466–70.Google Scholar
84Maizels, M, Blumenfeld, A, Burchette, R.A combination of riboflavin, magnesium, and feverfew in migraine prophylaxis: a randomized trial. Headache. 2004;44:885–90.Google Scholar
85Sandor, P, Di Clemente, L, Coppola, G, et al.Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized, controlled trial. Neurology. 2005;64:713–15.Google Scholar
86Peikert, A, Wilimzig, C, Kohne-Volland, R.Prophylaxis of migraine with oral magnesium: results from a prospective, multicentre, placebo-controlled and double blind randomized study. Cephalalgia. 1996;16:257–63.CrossRefGoogle Scholar
87Pfaffenrath, V, Wessely, P, Meyer, C, et al.Magnesium in the prophylaxis of migraine- a double blind, placebo controlled study. Cephalalgia. 1996;16:436–40.CrossRefGoogle Scholar
88Köseoglu, E, Talaslioglu, A, Gönül, AS, M, Kula. The effects of magnesium prophylaxis in migraine without aura. Magnes Res. 2008 Jun;21(2):101–8.Google Scholar
89Lipton, RB, Gobel, K, Einhaupl, KM, Wilks, K, Mauskop, A.Petasites hybridus root (butterbur) is an effective preventative treatment for migraine. Neurology. 2004;63:2240–4.Google Scholar
90Diener, H, Rahlfs, VW, Danesch, U.The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol. 2004;51:89–97.Google Scholar
91Pfaffenrath, V, Diener, H, Fischer, M, Friede, M, Henneicke-von Zepelin. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis- a double blind, multicentre, randomized placebo controlled dose-response study. Cephalalgia. 2002;22:523–32.Google Scholar
92Murphy, JJ, Heptinstall, S, Mitchell, JR.Randomised double blind placebo controlled trial of feverfew in migraine prevention. Lancet. 1988;8604:189–92.Google Scholar
93Diener, H, Pfaffenrath, V, Schnitker, J, Friede, M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg TID feverfew CO2 extract (MIG-99) in migraine prevention- a randomized, double-blind, multicentre, placebo controlled study. Cephalalgia. 2005;25:1031–41.Google Scholar
94DeWeerdt, CJ, Bootsma, HPR, Hendriks, H.Herbal medicines in migraine prevention. Phytomedicine. 1996;3(3):225–30.Google Scholar
95Evers, S, Vollmer-Haase, J, Schwaag, S, Rahmann, A, Husstedt, IW, Frese, A.Botulinum toxin A in the prophylactic treatment of migraine- a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004;24:838–43.Google Scholar
96Saper, J, Mathew, N, Loder, E, DeGryse, R, VanDenburgh, AM.A double-blind, randomized, placebo-controlled comparison of botulinum toxin type A injection sites and doses in the prevention of episodic migraine. Pain Med. 2007;8(6):478–85.Google Scholar
97Relja, M, Poole, AC, Schoenen, J, Pascual, J, Lei, X, Thompson, C.A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A for the prophylaxis of episodic migraine headaches. Cephalalgia. 2007;27:492–503.Google Scholar
98Vo, AH, Satori, R, Jabbari, B, et al.Botulinum toxin type-A in the prevention of migraine: a double-blind controlled trial. Aviat Space Environ Med. 2007;78(5):B113–18.Google Scholar
99Aurora, SK, Gawel, M, Brandes, JL, Pokta, S, Van Denburgh, AM.Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized double blind placebo controlled exploratory study. Headache. 2007;47:486–99.Google Scholar
100Elkind, AH, O’Carroll, P, Blumenfeld, A, DeGryse, R, Dimitrova, R.A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain. 2006;7(10):688–96.Google Scholar
101Silberstein, S, Mathew, N, Saper, J, Jenkins, S.Botulinum toxin type A as a migraine preventative treatment. Headache. 2000;40:445–50.Google Scholar
102Anand, KS, Prasad, A, Singh, MM, Sharma, S, Bala, K.Botulinum toxin type A in prophylactic treatment of migraine. Am J Ther. 2006;13:183–7.Google Scholar
103Blumenfeld, AM, Schim, JD, Chippendale, TJ.Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache. 2008 Feb;48(2):210–20.Google Scholar
104Cady, R, Schreiber, C.Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache. 2008 Jun;48(6):900–13.Google Scholar
105Petri, S, Tölle, T, Straube, A, Pfaffenrath, V, Stefenelli, U, Ceballos-Baumann, A; Dysport Migraine Study Group. Botulinum toxin as preventive treatment for migraine: a randomized double-blind study. Eur Neurol. 2009;62(4):204–11.Google Scholar
106Chankrachang, S, Arayawichanont, A, Poungvarin, N, et al.Prophylactic botulinum type A toxin complex (Dysport®) for migraine without aura. Headache. 2011 Jan;51(12):52–63.Google Scholar
107Shuhendler, AJ, Lee, S, Siu, M, et al.Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy. 2009 Jul;29(7):784–91.Google Scholar
108Aurora, SK, Dodick, DW, Turkel, CC, DeGryse, RE, Silberstein, SD, Lipton, RB, Diener, HC, Brin, MF; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010 Jul;30(7):793–803.CrossRefGoogle Scholar
109Diener, HC, Dodick, DW, Aurora, SK, Turkel, CC, DeGryse, RE, Lipton, RB, Silberstein, SD, Brin, MF; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010 Jul;30(7):804–14.Google Scholar
110Bellevance, AJ, Meloche, JR.A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache. 1990;30:710–15.Google Scholar
111Osterman, PO.A comparison between placebo, pizotifen and divascan in migraine prophylaxis. Acta Neurologica Scandinavica. 1977;56:17–28.Google Scholar
112Sjaastad, O, Stensrud, P.Appraisal of BC-105 in migraine prophylaxis. Acta Neurologica Scandinavica. 1969;45:594–600.CrossRefGoogle ScholarPubMed
113Lawrence, ER, Hossain, M, Littlestone, W.Sanomigran for migraine prophylaxis; controlled multicentre trial in general practice. Headache. 1977;17:109–12.Google Scholar
114Carroll, JD, Maclay, WP.Pizotifen (BC-105) in migraine prophylaxis. Curr Med Res Opin. 1975:3(2): 68–71.Google Scholar
115Scottish Intercollegiate Guidelines Network. Diagnosis and management of headache in adults: a national clinical guideline (Guideline 107). Available at http://www.sign.ac.uk.Google Scholar
116Koch, HJ, Jurgens, TP.Antidepressants in long-term migraine prevention. Drugs. 2009;69:1–19.Google Scholar
117Members of the Task Force: Evers, S, Afra, J, Frese, A, Goadsby, PJ, Linde, M, May, A, Sandor, PS.EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol. 2009 16:968–81.Google Scholar
118Silberstein, S, Saper, J, Berenson, F, Somogyi, M, McCague, K, D’Souza, J.Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology. 2008 Feb 12;70(7):548–55.Google Scholar
119Alstadhaug, KB, Odeh, F, Salvesen, R, Bekkelund, SI.Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology. 2010 Oct 26;75(2):1527–32.Google Scholar
120Hagen, K, Albretsen, C, Vilming, ST, et al.Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia. 2009;29:221–32.CrossRefGoogle ScholarPubMed
121Diener, H-C, Dodick, DW, Goadsby, PJ, et al.Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia. 2009;29:1021–7.Google Scholar
122Peres, MF, Silberstein, S, Moreira, F, et al.Patients’ preference for migraine preventative therapy. Headache. 2007;47:540–5.Google Scholar
123Kowacs, PA, Piovesan, EJ, Tepper, SJ.Rejection and acceptance of possible side effects of migraine prophylactic drugs. Headache. 2009;49:1022–7.Google Scholar
124Members of the Task Force: Evers, S, Afra, J, Frese, A, Goadsby, PJ, Linde, M, May, A, Sandor, PS.EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Euro J Neurol. 2009;16:968–81.Google Scholar
125Dodick, DW, Freitag, F, Banks, J, et al, Capss-277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group non-inferiority trial in adult migraineurs. Clin Ther. 2009;31:542–59.Google Scholar
126Koch, HJ, Jurgens, TP.Antidepressants in long-term migraine prevention. Drugs. 2009;69:1–19.Google Scholar
127Bigal, ME, Lipton, RB, Biondi, J, Xiang, J, Hulihan, J.Weight change and clinical markers of cardiovascular disease risk during preventative treatment of migraine. Cephalalgia. 2009;29:1188–96.Google Scholar
128Jette, N, Patten, S, Williams, J, Becker, W, Wiebe, S.Comorbidity of migraine and psychiatric disorders-a national population-based study. Headache. 2008 Apr;48(4):501–16.Google Scholar
129Jelinski, SE, Magnusson, JE, Becker, WJ; CHORD Study Group. Factors associated with depression in patients referred to headache specialists. Neurology. 2007 Feb 13;68(7):489–95.Google Scholar
130Hamelsky, SW, Lipton, RB.Psychiatric comorbidity of migraine. Headache. 2006 Oct;46(9):1327–33.Google Scholar
131Lam, RW, Kennedy, SH, Grigoriadis, S, et al.Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. IIIx. PharmacotherapyJ Affect Disord. J Affect Disord. 2009 Oct;117 Suppl 1:S26–43.Google Scholar
132Pringsheim, T, Davenport, WJ, Becker, WJ.Prophylaxis of migraine headache. CMAJ. 2010 Apr 20;182(7):269–76.Google Scholar
133Guaiana, G, Barbui, C, Hotopf, M.Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev. 2003;(2):CD004186. Review.Google Scholar
134Jelinski, SE, Becker, WJ, Christie, SN, et al.Clinical features and pharmacological treatment of migraine patients referred to headache specialists in Canada. Cephalalgia. 2006;26:578–88.Google Scholar
135Watson, CP, Vernich, L, Chipman, M, Reed, K.Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology. 1998 Oct;51(4):1166–71.Google Scholar
136Swinson RP and the Working Group. Clinical Practice Guidelines: Management of anxiety disorders. Can J Psychiat. 2006;51 (Suppl 2): 1S–90.Google Scholar
137Davidson, JR, Feltner, DE, Dugar, A.Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs. Prim Care Companion J Clin Psychiatry. 2010;12(2). pii: PCC. 09r00772.Google Scholar
138Silberstein, SD, Dodick, D, Freitag, F, et al.Pharmacological approaches to managing migraine and associated comorbidities-clinical considerations for monotherapy versus polytherapy. Headache. 2007 Apr;47(4):585–99.Google Scholar
139Mula, M, Sander, JW.Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 2007;30:555–67.CrossRefGoogle ScholarPubMed
140Ko, DT, Hebert, PR, Coffey, CS, Sedrakyan, A, Curtis, JP, Krumholz, HM: B-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002; 288:351–7.Google Scholar
141Gerstman, BB, Jolson, HM, Bauer, M, Cho, P, Livingston, JM, Platt, R.The incidence of depression in new users of beta-blockers and selected antihypertensives. J Clin Epidemiol. 1996 Jul;49(7):809–15.Google Scholar
142Gillman, PK.Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Brit J Pharmacol. 2007;151:737–48.Google Scholar
143Cipriani, A, Furukawa, TA, Salanti, G, et al.Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009 Feb 28;373(9665):746–58.CrossRefGoogle ScholarPubMed
144Scottish Intercollegiate Guidelines Network. Diagnosis and management of headache in adults: a national clinical guideline (Guideline 107). Available at http://www.sign.ac.uk.Google Scholar
145Schulman, EA, Lake, AE III, Goadsby, PJ, et al.Defining Refractory Migraine and Refractory Chronic Migraine: Proposed Criteria From the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008;48:778–82.Google Scholar
146Lipton, RB, Silberstein, SD, Saper, JR, Bigal, ME, Goadsby, PJ.Why headache treatment fails. Neurology. 2003;60:1064–70.Google Scholar
147Evans, RW, Pascual, J, Lainez, MJA, Leira, R.Bending the Rule of Monotherapy for Migraine Prevention? Headache. 2005;45:748–50.Google Scholar
148Peterlin, BL, Calhoun, AH, Siegel, S, Mathew, NT.Rational Combination Therapy in Refractory Migraine. Headache. 2008;48:805–19.Google Scholar
149Pascual, J, Rivas, MT, Leira, R.Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand. 2007:115:81-3.Google Scholar
150Martínez, HR, Londoño, O, Cantú-Martínez, L, del Carmen Tarín, L, Castillo, CD.Topiramate as an adjunctive treatment in migraine prophylaxis. Headache. 2003 Nov-Dec;43(10):1080–4.Google Scholar
151Pascual, J, Leira, R, Láinez, JM.Combined therapy for migraine prevention? Clinical experience with a b-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia. 2003;23:961–2.Google Scholar
152Keskinbora, K, Aydinli, I.Adouble-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg. 2008;110:979–84.Google Scholar
153Fox, AW, Diamond, ML, Spierings, ELH.Migraine during pregnancy. CNS Drugs. 2005;19(6):465–81.Google Scholar
154Menon, R, Bushnell, CD.Headache and pregnancy. Neurologist. 2008;14:108–19.Google Scholar
155Silberstein, SD.Headaches in pregnancy. J Headache Pain. 2005 Sep;6(4):172–4.Google Scholar
156Goadsby, PJ, Goldberg, J, Silberstein, SD.Migraine in pregnancy. BMJ. 2008;336:1502–4.Google Scholar
157Pfaffenrath, V, Rehm, M.Migraine in pregnancy. Drug Safety. 1998 Nov;19(5):383–8.Google Scholar
158Macintyre, PE, Schug, SA, Scott, DA, Visser, EJ, Walker, SM; APM: SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine (2010), Acute Pain Management: Scientific Evidence (3rd edition), ANZCA & FPM, Melbourne.Google Scholar
159Payne, J L, Meltzer-Brody, S.Antidepressant Use During Pregnancy: Current Controversies and Treatment Strategies. Clin Obstet Gynecol. 2009;52(3):469–82.Google Scholar
160Nulman, I, Rovet, J, Stewart, DE, et al.Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002 Nov;159(11):1889–95.Google Scholar
161Nulman, I, Rovet, J, Stewart, DE, et al.Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997 Jan 23;336(4): 258–62.Google Scholar
162MacGregor, EA.Migraine in pregnancy and lactation: a clinical review. J Fam Plann Reprod Health Care. 2007;33(2):83–93.Google Scholar
163Beaton, K.Health professional letter, Drug information. Janssen-Ortho. May 31, 2010.Google Scholar
164Lucas, S.Medication use in the treatment of migraine during pregnancy and lactation. Curr Pain Headache Rep. 2009 Oct; 13(5):392–8.Google Scholar
165Ito, S.Drug therapy for breast-feeding women. N Engl J Med. 2000; 343(2):118–26.Google Scholar
166Lanza di Scalea, T, Wisner, KL.Antidepressant medication use during breastfeeding. Clin Obstet Gynecol. 2009; 52(3):483–97.Google Scholar
167Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001; 108:776–89.Google Scholar
168Pryse-Phillips, WEM, Dodick, DW, Edmeads, JG, et al.Guidelines for the diagnosis and management of migraine in clinical practice. CMAJ. 1997;156:1273–87.Google Scholar
169Evans, RW, Bigal, ME.Grosberg, B, Lipton, RB.Target doses and titration schedules for migraine preventive medications. Headache. 2006;46:160–4.Google Scholar
170Purdy, RA.Headache in adults. In: Gray, J, editor. Therapeutic choices. 5th ed. Ottawa: Canadian Pharmacists Association; 2007. p. 169–85.Google Scholar
171Jellin, JM, Gregory, PJ, et al.Pharmacist’s letter/prescriber’s letter natural medicines comprehensive database. 10th ed. Stockton, CA: Therapeutic Research Faculty; 2008.Google Scholar
172Briggs, GG, Freeman, RK, Yaffe, SJ.Drugs in pregnancy and lactation. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.Google Scholar
173Repchinsky, C, editor-in-chief. The compendium of pharmaceuticals and specialties. The Canadian drug reference for health professionals. Ottawa: Canadian Pharmacists Association; 2009.Google Scholar
174Sauro, KM, Becker, WJ.Multidisciplinary treatment for headache in the Canadian healthcare setting. Can J Neurol Sci. 2008 Mar;35(1):46–56.Google Scholar
175Sauro, KM, Becker, WJ.The stress and migraine interaction. Headache. 2009 Oct;49(9):1378–86.Google Scholar
176Wöber, C, Holzhammer, J, Zeitlhofer, J, Wessely, P, Wöber-Bingöl, C.Trigger factors of migraine and tension-type headache: experience and knowledge of the patients. Headache Pain. 2006 Sep;7(4):188–95.Google Scholar
177Martin, PR.Behavioral Management of Migraine Headache Triggers: Learning to Cope with Triggers. Curr Pain Headache Rep. 2010;14:221–7.Google Scholar
178Kelman, L.The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27(5):394–402.Google Scholar
179Robbins, L.Precipitating factors in migraine: a retrospective review of 494 patients. Headache. 1994;34:214–6.Google Scholar
180Alpay, K, Ertas, M, Orhan, EK, Ustay, DK, Lieners, C, Baykan, B.Diet restriction in migraine, based on IgG against foods: a clinical double-blind, randomised, cross-over trial. Cephalalgia. 2010 Jul;30(7):829–37.Google Scholar
181Pascual, J, Oterino, A.IgG-mediated allergy: a new mechanism for migraine attacks? Cephalalgia. 2010 Jul;30(7):777–9.Google Scholar
182Sun-Edelstein, C, Mauskop, A.Foods and supplements in the management of migraine headaches. Clin J Pain. 2009 Jun;25(5):446–52.Google Scholar
183Calhoun, AH, Ford, S.Behavioral sleep modifications may revert transformed migraine to episodic migraine. Headache. 2007;45:1178–83.Google Scholar
184Borkum, JM.Chronic headaches: Biology, psychology, and behavioral treatment. Lawrence Erlbaum Associates, Publishers, Mahwah, New Jersey 2007.Google Scholar
185Rains, JC, Penzien, DB, McCrory, DC, Gray, RN.Behavioral headache treatment: history, review of the empirical literature, and methodological critique. Headache. 2005;45 Suppl 2:S92–109.Google Scholar
186Campbell, JK, Penzien, DB, Wall, EM.Evidenced-Based Guidelines For Migraine Headache: Behavioral and Physical Treatments. http://www.aan.com/professionals/practice/pdfs/gl0089.pdfGoogle Scholar
187Silberstein SD and the US Headache Consortium. Practice Parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Neurology. 2000;55:754–62.Google Scholar
188Pryse-Phillips, WE, Dodick, DW, Edmeads, JG, et al.Guidelines for the nonpharmacologic management of migraine in clinical practice. Canadian Headache Society. CMAJ. 1998 Jul 14;159(1):47–54.Google Scholar
189Scottish Intercollegiate Guidelines Network. Diagnosis and management of headache in adults: a national clinical guideline (Guideline 107). Available at http://www.sign.ac.uk.Google Scholar
190Penzien, DB, Rains, JC, Andrasik, F.Behavioral management of recurrent headache: Three decades of experience and empiricism. Appl Psychophysiol Biofeedback. 2002 Jun;27(2):163–81.Google Scholar
191Dittrich, SM, Günther, V, Franz, G, Burtscher, M, Holzner, B, Kopp, M.Aerobic exercise with relaxation: influence on pain and psychological well-being in female migraine patients. Clin J Sport Med. 2008 Jul;18(4):363–5.Google Scholar
192Lemstra, M, Stewart, B, Olszynski, WP.Effectiveness of multidisciplinary intervention in the treatment of migraine: a randomized clinical trial. Headache. 2002;42:845–54.Google Scholar
193Magnusson, JE, Riess, CM, Becker, WJ.Effectiveness of a multidisciplinary treatment program for chronic daily headache. Can J Neurol Sci. 2004 Feb;31(1):72–9.Google Scholar
194Gunreben-Stempfle, B, Griessinger, N, Lang, E, Muehlhans, B, Sittl, R, Ulrich, K.Effectiveness of an intensive multidisciplinary headache treatment program. Headache. 2009 Jul;49(7):990–1000.Google Scholar
195Holroyd, KA, Cottrell, CK, O’Donnell, FJ, et al.Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ. 2010 Sep 29;341:c4871. doi: 10.1136/bmj.c4871.Google Scholar
196AGREE, Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care. 2003;12:18–23.Google Scholar
197Peres, MF, Silberstein, S, Moreira, F, et al.Patients’ preference for migraine preventative therapy. Headache. 2007;47:540–5.Google Scholar
198Kowacs, PA, Piovesan, EJ, Tepper, SJ.Rejection and acceptance of possible side effects of migraine prophylactic drugs. Headache. 2009;49:1022–7.Google Scholar
199Becker, WJ, Gladstone, JP, Aubé, M.Migraine prevalence, diagnosis, and disability. Can J Neurol Sci. 2007;34:S3–9.Google Scholar
200Becker, WJ, Gawel, M, Mackie, G, South, V, Christie, SN. Migraine treatment. Can J Neurol Sci. 2007;34:S10–19.Google Scholar
201Becker, WJ, Giammarco, R, Wiebe, V.Moving forward to improve migraine management in Canada. Can J Neurol Sci. 2007;34:S20–6.Google Scholar
202Headache Classification Subcommittee of the International Headache Society The International Classification of headache disorders. Cephalalgia. 2004;24(Suppl 1):1–160.Google Scholar
203Ad Hoc Committee on Classification of Headache. CMAJ. 1962;179:717–18.Google Scholar
204Guyatt, GH, Oxman, AD, Vist, GE, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336;924–6.Google Scholar
205Guyatt, GH, Oxman, AD, Kunz, Ret al.What is “quality of evidence” and why is it important to clinicians? BMJ. 2008 May 3;336(7651):995–8.Google Scholar
206Sauro, KM, Rose, MS, Becker, WJ, et al.HIT-6 and MIDAS as Measures of Headache Disability in a Headache Referral Population. Headache. 2010 Mar;50(3):383–95.Google Scholar
207Silberstein, SD, Winner, PK, Chmiel, JJ.Migraine preventive medication reduces resource utilization. Headache. 2003;43(3):171–8.Google Scholar
208Etemad, LR, Yang, W, Globe, D, Barlev, A, Johnson, KA.Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm. 2005;11(2):137–44.Google Scholar
209Silberstein, SD, Feliu, AL, Rupnow, MF, Blount, AC, Boccuzzi, SJ.Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost. Headache. 2007;47:500–10.Google Scholar